NCT07184840View on ClinicalTrials.gov

Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions
Neuromyelitis Optica Spectrum Disorder Attack
Interventions
DRUG

Intravenous Methylprednisolone (IVMP)

IVMP arm: 1000mg methylprednisolone x5d, oral prednisone 60mg, 5mg weekly decline + antibiotics

DRUG

Complement protein C5 inhibitor

"IVMP+Eculizumab arm: eculizumab (900 mg) will be administered intravenously once per week for a total of four doses (days 1, 8, 15, and 22) in conjunction with IVMP and oral prednisone (60mg, 5mg weekly decline).~All enrolled patients will receive antibiotic prophylaxis against N meningitidis."

Trial Locations (1)

300052

RECRUITING

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University General Hospital

OTHER

NCT07184840 - Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder | Biotech Hunter | Biotech Hunter